Medical Information Only. Always consult your healthcare provider before enrolling in any clinical trial.

NCT03203239 · ClinicalTrials.gov registry record · NA

Red Light Treatment in Peripheral Artery Disease

A NA study of Peripheral Artery Disease and Vasodilation, sponsored by University of Alabama at Birmingham.

Recruiting
Registry status
NA
Development phase
40
Enrollment target
1
Study location

NCT03203239 is a NA study of Peripheral Artery Disease and Vasodilation that is actively recruiting participants, run by University of Alabama at Birmingham. The registered enrollment target is 40 participants, below the 126-participant average among 50 other Peripheral Artery Disease trials with a reported enrollment target (68% lower). The trial reports 1 study location across 1 state.

View on ClinicalTrials.gov ↗

View your shortlist →

The verdict

NCT03203239, a NA study of Peripheral Artery Disease and Vasodilation, is actively recruiting participants, sponsored by University of Alabama at Birmingham.

RECRUITING
Registry status
NA
Development phase
40 participants
Enrollment target
1
Study location

Study Summary

Subjects with a known diagnosis of peripheral artery disease as measured by an abnormal ankle brachial index (\<.9 or \>1.1) will undergo a single 5 min exposure of 670 nm light, 1 cm above the gastrocnemius muscle. Blood flow will be measured by infusion of ultrasound contrast and subsequent acquisition of ultrasound images. 2 blood samples will be collected for measurement of nitric oxide metabolites.

Interventions

  • DEVICE Red Light (670 nm energy)
  • DRUG Octafluoropropane

Study Locations (1)

Wisconsin

  • Medical College of Wisconsin - Milwaukee

Trial Details

FieldValue
Enrollment Target 40 participants
Start Date 2018-01-17
Est. Completion 2027-12-31
Phase NA

Sponsor

University of Alabama at Birmingham

1,160 total trials

What the Registry Record Tells You About NCT03203239

The ClinicalTrials.gov registry entry for NCT03203239 describes a study currently listed as recruiting, categorized as NA. The registered enrollment target is 40 participants, a figure that helps gauge the scale of data the investigators plan to collect, below the 126-participant average among 50 other Peripheral Artery Disease trials with a reported enrollment target (68% lower). The listed sponsor is University of Alabama at Birmingham, which has 1,160 total studies on file at ClinicalTrials.gov.

The record links to 3 conditions, with Peripheral Artery Disease appearing as the primary indexed condition, and to 2 interventions - of which Red Light (670 nm energy) is the first listed.

NCT03203239 reports 1 study location spanning 1 distinct geographic area - top geographies include Wisconsin.

Frequently Asked Questions

What is clinical trial NCT03203239 about?

NCT03203239 is a clinical study titled "Red Light Treatment in Peripheral Artery Disease". Subjects with a known diagnosis of peripheral artery disease as measured by an abnormal ankle brachial index (\<.9 or \>1.1) will undergo a single 5 min exposure of 670 nm light, 1 cm above the gastrocnemius muscle. Blood flow will be measured by infusion of ultrasound contrast and subsequent acquis...

What is the current status of trial NCT03203239?

This trial is currently recruiting. It is a NA study. The enrollment target is 40 participants. The study started on 2018-01-17. Estimated completion is 2027-12-31.

What conditions does trial NCT03203239 study?

This clinical trial studies the following conditions: Peripheral Artery Disease, Vasodilation, Claudication, Intermittent.

What interventions are being tested in trial NCT03203239?

The interventions under investigation include: Red Light (670 nm energy) (DEVICE), Octafluoropropane (DRUG).

Who is sponsoring clinical trial NCT03203239?

This trial is sponsored by University of Alabama at Birmingham, which has 1,160 total clinical trials registered on ClinicalTrials.gov.

Where is trial NCT03203239 being conducted?

This trial has 1 study location across Wisconsin. Contact the study sites directly through ClinicalTrials.gov for enrollment availability.

Similar trials for Peripheral Artery Disease

Matched on the same primary condition, ranked to surface studies in the same phase first, then by recruiting status, no relevance scoring or editorial curation.

Data sourced from official public datasets. See our methodology for details. Retrieved and formatted by PlainTrial Editorial

Every figure on PlainTrial is rendered directly from the ClinicalTrials.gov registry, no number is typed in by an editor. This page mirrors this trial's own ClinicalTrials.gov registry record, live from the dataset. See our editorial standards & corrections policy, the methodology behind these numbers, or report a data error.